Editas Medicine Announces Third Quarter 2024 Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT)
November 5, 2024 4:19 PM ESTChardan Capital Markets analyst Geulah Livshits reiterated a Buy rating and $12.00 price target on Editas Medicine (NASDAQ: EDIT).
The analyst comments "EDIT (Buy, PT $12): 3Q24 Results; Reni-cel Data at ASH; In Vivo Updates in 1Q25. On 4 November, Editas Medicine reported 3Q24 results and... More
Editas Medicine (EDIT) PT Lowered to $5 at Barclays
November 5, 2024 5:23 AM ESTBarclays analyst Gena Wang lowered the price target on Editas Medicine (NASDAQ: EDIT) to $5.00 (from $7.00) while maintaining a Equalweight rating.
The analyst comments "Key takeaways. 3Q24 PR was incremental following recent strategic update (see EDIT - Strategic update mixed, 10/22/2024). Reni-cel (EDIT-301): Mgmt. reiterated... More
Editas Medicine (EDIT) PT Lowered to $8 at Truist Securities
November 4, 2024 12:25 PM ESTTruist Securities analyst Joon Lee lowered the price target on Editas Medicine (NASDAQ: EDIT) to $8.00 (from $12.00) while maintaining a Buy rating.
The analyst comments "3Q24: No surprises on the quarter post recent announcements (our prior takes - HERE and HERE). EDIT... More
